Receptor News and Research

RSS

A weight-loss drug eased knee arthritis pain in two major trials

Retatrutide effectively alleviates knee pain and enhances mobility in obese osteoarthritis patients, but long-term safety and joint health remain uncertain.

10 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

Australian-developed MND therapy advances to Phase 2 clinical trial

An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.

9 Nov 2026

CAR-T cell therapy shows promising early results for stiff person syndrome

A multicenter clinical trial evaluating chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for stiff person syndrome (SPS), a rare autoimmune neurologic disorder, has produced promising early results.

9 Nov 2026

Study reveals how astrocytes regulate brain blood flow and activity

What happens in our brains when we experience sensory stimulation? During everyday activities such as jogging, reading, or listening to music, sensory inputs activate neurons in specific brain regions.

9 Nov 2026

Could a daily supplement keep blood vessels healthier as we age?

The study highlights a multi-compound nutritional supplement's potential to improve blood vessel function and lower blood pressure, aiding vascular health.

9 Nov 2026

Qureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight's Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum's PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum's lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

From Qureight 9 Nov 2026

CAR T-cell therapy shows promise for difficult-to-treat lupus

A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from researchers at Hospital for Special Surgery (HSS).

8 Nov 2026

ZEUS trial challenges assumptions about targeting inflammation in heart disease

Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less straightforward than once thought.

8 Nov 2026

GLP-1 weight-loss drugs may change what you crave, not just how much you eat

A prospective observational pilot study of 38 adults without diabetes found that three months of semaglutide or tirzepatide treatment was associated with an average weight loss of 7.2 kg, reduced food cravings, increased satiety, and improved self-reported hunger control. Most participants reported smaller meal portions, while some experienced changes in food preferences, although the study could not establish whether the medications directly caused these behavioral changes.

8 Nov 2026

Frequent anxiety may reflect worsening cognitive function in Alzheimer's disease

Ask the family of someone with Alzheimer's disease what the hardest part is, and the answer is not always the forgetting. Sometimes it is the pacing.

6 Nov 2026

Harvard-led team receives $7 million to develop AI co-scientists for cancer research

A team led by Marinka Zitnik, associate professor of biomedical informatics in the Blavatnik Institute at Harvard Medical School, has received a grant of nearly $7 million from Cancer Grand Challenges to create artificial intelligence (AI) "co-scientists" that help cancer researchers analyze data, generate hypotheses, and suggest new experiments, speeding new knowledge and therapies.

6 Nov 2026

$Refractory lichen planus-like lesions reveal underlying systemic T-cell lymphoma$

Refractory lichen planus-like lesions reveal underlying systemic T-cell lymphoma

A 61-year-old man had a 2-year history of painful mucosal lesions and pruritic violaceous plaques on the trunk and extremities.

6 Nov 2026

Two common forever chemicals linked to higher incidence of ER-negative breast cancer

Women with higher blood levels of two common per- and polyfluoroalkyl substances, also familiarly known as PFAS, were more likely to develop estrogen receptor-negative, or ER-negative, breast cancer, according to a new study by the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services (HHS).

6 Nov 2026

Towards a new approach to treating chronic blood disorders

A previously unrecognised weakness in the immune defenses against certain blood neoplasms could offer a promising target for future treatments.

6 Nov 2026

Study shows opposite synaptic mechanisms cause identical cognitive deficits

A research team led by Dr. SHENG Nengyin of the Kunming Institute of Zoology (KIZ) of the Chinese Academy of Sciences has reframed ZC4H2-associated rare disorder (ZARD)-a disorder marked by intellectual disability, developmental delays, muscle weakness, and other neurological or physical abnormalities-as a "disease spectrum" rather than a condition driven by a single mechanism.

5 Nov 2026

Targeting brain protein may help treat MEF2C-related neurological disorders

A particular signaling protein in the brain could be a therapeutic target for neurological disorders arising from the deletion of the autism-linked gene MEF2C, University of Illinois Urbana-Champaign researchers found in a new mouse study.

4 Nov 2026

Faulty cellular recycling may link pulmonary arterial hypertension to brain damage

A commentary in The Journal of Clinical Investigation examines evidence linking pulmonary arterial hypertension (PAH) to cerebellar abnormalities, focusing on impaired lysosomal lipid metabolism, oxysterol accumulation, and microglial inflammation. Findings from human imaging, mouse models, and cultured cells suggest that NCOA7 may help protect against these changes, although the proposed mechanisms and therapeutic implications require further investigation.

4 Nov 2026

Targeted nanoimmunotherapy reduces atherosclerotic plaque burden in mice

This new article publication from Acta Pharmaceutica Sinica B discusses a targeted nanoimmunotherapy designed to restore macrophage clearance of dying cells, promote an anti-inflammatory phenotype, and reduce atherosclerotic plaque burden in mice.

4 Nov 2026

Genetic variant tied to liver injury from blood pressure drugs

This new article publication from Acta Pharmaceutica Sinica B discusses the clinical features and genetic associations of rare liver injury caused by antihypertensive medications.

4 Nov 2026

Receptor News and Research

A weight-loss drug eased knee arthritis pain in two major trials

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Australian-developed MND therapy advances to Phase 2 clinical trial

CAR-T cell therapy shows promising early results for stiff person syndrome

Study reveals how astrocytes regulate brain blood flow and activity

Could a daily supplement keep blood vessels healthier as we age?

Qureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

CAR T-cell therapy shows promise for difficult-to-treat lupus

ZEUS trial challenges assumptions about targeting inflammation in heart disease

GLP-1 weight-loss drugs may change what you crave, not just how much you eat

Frequent anxiety may reflect worsening cognitive function in Alzheimer's disease

Harvard-led team receives $7 million to develop AI co-scientists for cancer research

Refractory lichen planus-like lesions reveal underlying systemic T-cell lymphoma

Two common forever chemicals linked to higher incidence of ER-negative breast cancer

Towards a new approach to treating chronic blood disorders

Study shows opposite synaptic mechanisms cause identical cognitive deficits

Targeting brain protein may help treat MEF2C-related neurological disorders

Faulty cellular recycling may link pulmonary arterial hypertension to brain damage

Targeted nanoimmunotherapy reduces atherosclerotic plaque burden in mice

Genetic variant tied to liver injury from blood pressure drugs

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News